Functional Technologies Announces First Quarter 2012 Financial Results
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 02/28/12 -- Functional Technologies Corp. (TSX VENTURE: FEB) (the "Company") today reported operational and financial results for the first quarter ended November 30, 2011 ("Q1/12"). Amounts, unless specified otherwise, are expressed in Canadian dollars. The Company's Q1/12 consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"), reporting standards by which the Company has transitioned to from Canadian Generally Accepted Accounting Principles.
"Functional Technologies continues to accomplish substantial achievements in building technical and commercial value for our proprietary acrylamide-preventing as well as hydrogen sulphide-preventing yeast platforms, in alignment with our corporate goal to drive technologies from bench to commercialization. These lead programs continue to achieve significant third party validation for our core technologies, which has also translated into increasing requirements for management time and resources," said Mr. Christopher Morris, Functional Technologies' acting CEO.
Mr. Morris added, "As a result, we maintain our efforts to focus on and implement initiatives to optimize the Company's capital resources and streamline corporate as well as development activities, including an ongoing review by management of non-core programs associated with Phyterra Bio Inc. and Maritime Pulse Drying Inc., enabling the Company to continue to drive significant value from the Company's promising lead programs. With the intensifying technical and business development activities associated with both our lead programs, it is our belief that the coming year could be a significant evolutionary and transitional year for Functional Technologies."
Operating Highlights
During Q1/12, the Company:
Subsequent to quarter-end, the Company:
Financial Results
The Company incurred a net loss of $1.1 million during Q1/12, compared to a net loss of $0.7 million for the three months ended November 30, 2010 ("Q1/11"), representing an increase of $0.4 million due primarily to an increase in operating expenses and a decrease in government assistance.
Operating expenses, excluding stock-based compensation expenses, for Q1/12 were $1.2 million, compared to $0.9 million in Q1/11. The increase in operating expenses was attributed primarily to increases in research and development, legal and consulting expenses associated in part with elevated product development, business development, and marketing activities. Government funding in Q1/12 decreased by $0.1 million from $0.2 million in Q1/11 due to reduced R&D activities conducted by the Company's subsidiary Phyterra Bio Inc.
Liquidity and Outstanding Share Capital
As at November 30, 2011, the Company had cash and short-term investments of $3.1 million compared to $4.2 million as at August 31, 2011. As at November 30, 2011, the Company had working capital of $2.8 million compared to $3.9 million as at August 31, 2011.
As at February 28, 2012, Functional Technologies had 49,396,895 common shares issued and outstanding.
Additional Information
This news release should be read in conjunction with the Company's consolidated financial statements for the quarter ended November 30, 2011 and the notes thereto, together with the MD&A for the corresponding period, which are available on the Company's website and on SEDAR at .
About Functional Technologies Corp.
Functional Technologies develops and commercializes proprietary, advanced yeast-based solutions to significant challenges in the food, beverage and healthcare industries. The Company's platform improves the performance of innate yeast functions, and prevents the formation of naturally occurring toxins and contaminants that either affect final product quality or are classified by the World Health Organization as probable human carcinogens. Functional Technologies' lead technologies include yeasts that prevent and reduce the formation of the foul-smelling hydrogen sulphide (H2S) and the carcinogens acrylamide and ethyl carbamate (more commonly known as urethane), by-products of food and beverage processing. These contaminants are found in many commonly consumed items, such as fermented food products and alcoholic beverages, and baked and fried foods. With a head office in Vancouver, Functional Technologies Corp. has R&D operations in Prince Edward Island and Europe, as well as a U.S. sales office in Napa Valley, California. For more information, please visit our website at .
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Contacts:
Functional Technologies Corp.
Connie Chen, PhD
VP, Corporate Development and Communications
+1.647.282.5038
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.02.2012 - 08:00 Uhr
Sprache: Deutsch
News-ID 1087671
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
VANCOUVER, BRITISH COLUMBIA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 153 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Functional Technologies Announces First Quarter 2012 Financial Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
Functional Technologies Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
